While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the body's defences are unable to ...

Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class ...

CD163 might not be the most exciting name in the world, but behind it lies one of the body's most important defense receptors ...

Announced first in vivo clinical validation for ARCUS gene editing across two distinct programs including wholly owned PBGENE-HBV and partnered program ECUR-506 - - Commenced Phase 1 ELIMINATE-B ...

The US joins Moldova, Hong Kong, and New Zealand as countries to greenlight the company's Phase I trial of PBGENE-HBV.

The last few years have provided us with a new level of understanding of how chromosomes are replicated, segregated and read - and how their 3D organisation influences expression of individual genes ...

Hepatitis B and C still survive in the dark, driven by a lack of information, unhygienic medical procedures, and poor access ...

Multiple controls make the data convincing. The findings shed new light on the role of SATB1 in genome organization and will be of interest to those who study chromosome structure and nuclear ...

Occult HBV infection is defined by the existence of HBV DNA in serum, lymphoid cells (PBMC) and/or the liver and virus-genome replicative intermediates (i.e., covalently closed circular DNA ...

Compensated If HBV DNA ≥2000 IU/ml, treat If HBV DNA is 1–2000 IU/ml, treat if ALT is elevated Decompensated If HBV DNA is detectable, treat and refer for liver transplantation If HBV DNA is ...